Literature DB >> 24055703

Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.

Matthias Brendel1, Andreas Delker, Christina Rötzer, Guido Böning, Janette Carlsen, Clemens Cyran, Erik Mille, Franz Josef Gildehaus, Paul Cumming, Karlheinz Baumann, Harald Steiner, Christian Haass, Jochen Herms, Peter Bartenstein, Axel Rominger.   

Abstract

We previously investigated the progression of β-amyloid deposition in brain of mice over-expressing amyloid-precursor protein (APP-Swe), a model of Alzheimer's disease (AD), in a longitudinal PET study with the novel β-amyloid tracer [(18)F]-florbetaben. There were certain discrepancies between PET and autoradiographic findings, which seemed to arise from partial volume effects (PVE). Since this phenomenon can lead to bias, most especially in the quantitation of brain microPET studies of mice, we aimed in the present study to investigate the magnitude of PVE on [(18)F]-florbetaben quantitation in murine brain, and to establish and validate a useful correction method (PVEC). Phantom studies with solutions of known radioactivity concentration were performed to measure the full-width-at-half-maximum (FWHM) resolution of the Siemens Inveon DPET and to validate a volume-of-interest (VOI)-based PVEC algorithm. Several VOI-brain-masks were applied to perform in vivo PVEC on [(18)F]-florbetaben data from C57BL/6(N=6) mice, while uncorrected and PVE-corrected data were cross-validated with gamma counting and autoradiography. Next, PVEC was performed on longitudinal PET data set consisting of 43 PET scans in APP-Swe (13-20months) and age-matched wild-type (WT) mice using the previously defined masks. VOI-based cortex-to-cerebellum ratios (SUVR) were compared for uncorrected and PVE-corrected results. Brains from a subset of transgenic mice were ultimately examined by autoradiography ex vivo and histochemistry in vitro as gold standard assessments, and compared to VOI-based PET results. The phantom study indicated a FWHM of 1.72mm. Applying a VOI-brain-mask including extracerebral regions gave robust PVEC, with increased precision of the SUVR results. Cortical SUVR increased with age in APP-Swe mice compared to baseline measurements (16months: +5.5%, p<0.005; 20months: +15.5%, p<0.05) with uncorrected data, and to a substantially greater extent with PVEC (16months: +12.2% p<0.005; 20months: +36.4% p<0.05). WT animals showed no binding changes, irrespective of PVEC. Relative to autoradiographic results, the error [%] for uncorrected cortical SUVR was 18.9% for native PET data, and declined to 4.8% upon PVEC, in high correlation with histochemistry results. We calculate that PVEC increases by 10% statistical power for detecting altered [(18)F]-florbetaben uptake in aging APP-Swe mice in planned studies of disease modifying treatments on amyloidogenesis.
© 2013.

Entities:  

Keywords:  APP-Swe; Alzheimer's disease; BAS; BGR; CBL; CTX; ET; FRO; FWHM; Field of View; FoV; GTM; HGL; HIP; K670N; M671L; MGM; MIX; MIX-HI; MIX-LO; Müller-Gärtner Method; PSF; PVE; PVEC; Partial volume effect correction; RMSE [%]; SPI; SRR; SUP; Small animal PET; TG; WT; [(18)F]-florbetaben; background surround VOI; basal surround VOI; cerebellum; combined brain structure VOI except frontal cortical target VOI and cerebellum; cortex; effects of therapy; frontal surround VOI; full width at half maximum; geometric transfer matrix; harderian gland VOI; high uptake part of subdivided MIX VOI; hippocampus; low uptake part of subdivided MIX VOI; mutation of amyloid precursor protein; partial volume effect correction; partial volume effects; point spread function; root–mean–square-error percentage; single extracerebral surround VOI; spinal surround VOI; superior surround VOI; transgenic; wild-type; ß-amyloid

Mesh:

Substances:

Year:  2013        PMID: 24055703     DOI: 10.1016/j.neuroimage.2013.09.017

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  15 in total

1.  Preclinical Comparison of the Amyloid-β Radioligands [(11)C]Pittsburgh compound B and [(18)F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis.

Authors:  Ann-Marie Waldron; Jeroen Verhaeghe; Leonie wyffels; Mark Schmidt; Xavier Langlois; Annemie Van Der Linden; Sigrid Stroobants; Steven Staelens
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

Review 2.  How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease?

Authors:  Darryl Bannon; Anne M Landau; Doris J Doudet
Journal:  Curr Neurol Neurosci Rep       Date:  2015-08       Impact factor: 5.081

3.  Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models.

Authors:  Matthias Brendel; Anna Jaworska; Eric Grießinger; Christina Rötzer; Steffen Burgold; Franz-Josef Gildehaus; Janette Carlsen; Paul Cumming; Karlheinz Baumann; Christian Haass; Harald Steiner; Peter Bartenstein; Jochen Herms; Axel Rominger
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

Review 4.  Beta-amyloid imaging with florbetaben.

Authors:  Osama Sabri; John Seibyl; Christopher Rowe; Henryk Barthel
Journal:  Clin Transl Imaging       Date:  2015-02-12

5.  In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [(18)F]flutemetamol.

Authors:  Anniina Snellman; Johanna Rokka; Francisco R López-Picón; Olli Eskola; Mario Salmona; Gianluigi Forloni; Mika Scheinin; Olof Solin; Juha O Rinne; Merja Haaparanta-Solin
Journal:  EJNMMI Res       Date:  2014-08-01       Impact factor: 3.138

6.  Blunted cerebrovascular response is associated with elevated beta-amyloid.

Authors:  Jason-Flor V Sisante; Eric D Vidoni; Kiersten Kirkendoll; Jaimie Ward; Yumei Liu; Sarah Kwapiszeski; Rebecca Maletsky; Jeffrey M Burns; Sandra A Billinger
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-15       Impact factor: 6.200

7.  Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [ 18 F]PI-2620.

Authors:  Marie Willroider; Sigrun Roeber; Anja K E Horn; Thomas Arzberger; Maximilian Scheifele; Gesine Respondek; Osama Sabri; Henryk Barthel; Marianne Patt; Olena Mishchenko; Andreas Schildan; André Mueller; Norman Koglin; Andrew Stephens; Johannes Levin; Günter U Höglinger; Peter Bartenstein; Jochen Herms; Matthias Brendel; Leonie Beyer
Journal:  Front Neurol       Date:  2021-07-02       Impact factor: 4.003

8.  FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice.

Authors:  Behrooz H Yousefi; Boris von Reutern; Daniela Scherübl; André Manook; Markus Schwaiger; Timo Grimmer; Gjermund Henriksen; Stefan Förster; Alexander Drzezga; Hans-Jürgen Wester
Journal:  EJNMMI Res       Date:  2015-03-28       Impact factor: 3.138

9.  Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [(18)F]-Florbetaben PET Quantitation in Alzheimer's Model Mice.

Authors:  Felix Overhoff; Matthias Brendel; Anna Jaworska; Viktoria Korzhova; Andreas Delker; Federico Probst; Carola Focke; Franz-Josef Gildehaus; Janette Carlsen; Karlheinz Baumann; Christian Haass; Peter Bartenstein; Jochen Herms; Axel Rominger
Journal:  Front Neurosci       Date:  2016-02-29       Impact factor: 4.677

10.  In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 mice.

Authors:  Ann-Marie Waldron; Cindy Wintmolders; Astrid Bottelbergs; Jonathan B Kelley; Mark E Schmidt; Sigrid Stroobants; Xavier Langlois; Steven Staelens
Journal:  Alzheimers Res Ther       Date:  2015-12-15       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.